Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder marked by inattention, hyperactivity, and impulsivity. It affects approximately 7.6% of children aged 3-12 and 5.6% of adolescents aged 12-18, based on a 2023 global prevalence study. There is a growing focus on innovative attention deficit hyperactivity disorder therapeutics, such as next-generation stimulants, non-stimulant options, and extended-release formulations. Attention deficit hyperactivity disorder pipeline analysis by Expert Market Research examines the pipeline of drugs, both in clinical and preclinical stages, aimed at addressing ADHD symptoms. Increasing awareness, enhanced diagnosis, and demand for safer long-term treatments are expected to accelerate the development of attention deficit hyperactivity disorder therapeutic products in the coming years.
Report Coverage
The Attention Deficit Hyperactivity Disorder Pipeline Analysis Report by Expert Market Research gives comprehensive insights into attention deficit hyperactivity disorder therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for attention deficit hyperactivity disorder. The attention deficit hyperactivity disorder report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The attention deficit hyperactivity disorder pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with attention deficit hyperactivity disorder treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to attention deficit hyperactivity disorder.
Attention Deficit Hyperactivity Disorder Pipeline Outlook
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition marked by inattention, hyperactivity, and impulsivity. It typically emerges in childhood and may persist into adulthood. ADHD occurs due to genetic, neurobiological, and environmental factors that affect brain development and neurotransmitter function, particularly in areas controlling attention and behavior regulation.
ADHD treatment includes behavioral therapy and medications. Stimulants like methylphenidate and non-stimulants such as atomoxetine or clonidine help improve focus and control impulsive behaviors. For instance, in May 2024, Tris Pharma received U.S. FDA approval for ONYDA XR, a once-daily, extended-release oral suspension of clonidine hydrochloride, offering the first liquid non-stimulant ADHD treatment with nighttime dosing.
Attention Deficit Hyperactivity Disorder Epidemiology
According to a 2023 global study, attention deficit hyperactivity disorder (ADHD) affects 7.6% of children aged 3–12 years and 5.6% of adolescents aged 12–18 years. In the United States, the Centers for Disease Control and Prevention reported that 11.4% of children aged 3–17 years (approximately 7 million) had been diagnosed with ADHD as of 2022. In the United Kingdom, adult ADHD prevalence is estimated at 3% to 4%.
Attention Deficit Hyperactivity Disorder – Pipeline Therapeutic Assessment
This section of the report covers the analysis of attention deficit hyperactivity disorder drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Prodrugs
- Peptides
- Biologics
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share (34.09%) of the total attention deficit hyperactivity disorder clinical trials. It is followed by Phase IV at 31.82%, Phase III at 18.18%, Phase I at 11.36%, and Early Phase I at 4.55%. The robust presence of advanced and late-stage trials reflects strong R&D progress, indicating promising future approvals that can positively shape the attention deficit hyperactivity disorder market landscape.
Attention Deficit Hyperactivity Disorder Pipeline Assessment Segmentation by Drug Classes
The drug molecule categories covered under the attention deficit hyperactivity disorder pipeline analysis include small molecules, prodrugs, peptides, and biologics. The attention deficit hyperactivity disorder report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for attention deficit hyperactivity disorder.
Non-stimulant therapies are gaining traction in the attention deficit hyperactivity disorder (ADHD) pipeline. For example, in December 2024, Qelbree (viloxazine extended-release), a novel serotonin-norepinephrine modulating agent, has been submitted for review in Canada by Knight Therapeutics. It is currently approved in the United States and is undergoing further clinical evaluation for various age groups and comorbid conditions, offering an alternative to traditional stimulants.
Attention Deficit Hyperactivity Disorder Clinical Trials – Key Players
The EMR report for the attention deficit hyperactivity disorder pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed attention deficit hyperactivity disorder therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in attention deficit hyperactivity disorder clinical trials:
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Corium, Inc.
- Supernus Pharmaceuticals, Inc.
- Ironshore Pharmaceuticals and Development, Inc.
- Neurocentria, Inc.
- Bazelet Nehushtan Ltd.
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Premier Research Group plc.
- Prometrika, LLC
- Takeda Development Center Americas, Inc.
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for attention deficit hyperactivity disorder. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of attention deficit hyperactivity disorder drug candidates.
Drug: Guanfacine hydrochloride (TAK-503)
TAK-503 is being studied by Shire (now part of Takeda) to evaluate its long-term safety and efficacy in children and adolescents with ADHD who have not responded well to stimulant treatments. TAK-503 is a prolonged-release formulation of guanfacine hydrochloride, which works by modulating noradrenaline transmission through α2-adrenergic receptors. It is a part of a phase IV study, which is examining how this medication impacts ADHD symptoms and whether it offers an effective alternative for patients who struggle with conventional stimulant medications.
Drug: HLD200
HLD200 is a delayed-release and extended-release methylphenidate capsule developed by Ironshore Pharmaceuticals and Development, Inc. It is undergoing phase III clinical development, where it is being evaluated for its efficacy, safety, and pharmacokinetics in children aged 4-5 years with ADHD. The objective is to examine the drug's therapeutic effects throughout the day when dosed in the evening.
Reasons To Buy This Report
The Attention Deficit Hyperactivity Disorder Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for attention deficit hyperactivity disorder. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within attention deficit hyperactivity disorder pipeline insights.
Key Questions Answered in the Attention Deficit Hyperactivity Disorder Pipeline Analysis Report
- Which companies/institutions are leading the attention deficit hyperactivity disorder drug development?
- What is the efficacy and safety profile of attention deficit hyperactivity disorder pipeline drugs?
- Which company is leading the attention deficit hyperactivity disorder pipeline development activities?
- What is the current attention deficit hyperactivity disorder commercial assessment?
- What are the opportunities and challenges present in the attention deficit hyperactivity disorder pipeline landscape?
- What is the efficacy and safety profile of attention deficit hyperactivity disorder pipeline drugs?
- Which company is conducting major trials for attention deficit hyperactivity disorder drugs?
- Which companies/institutions are involved in attention deficit hyperactivity disorder collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in attention-deficit hyperactivity disorder?
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report
Global Clinical Trials Market
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Attention Deficit Hyperactivity Disorder
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Attention Deficit Hyperactivity Disorder
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Attention Deficit Hyperactivity Disorder: Epidemiology Snapshot
- 5.1 Attention Deficit Hyperactivity Disorder Incidence by Key Markets
- 5.2 Attention Deficit Hyperactivity Disorder – Patients Seeking Treatment in Key Markets
- 6 Attention Deficit Hyperactivity Disorder: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Attention Deficit Hyperactivity Disorder: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Attention Deficit Hyperactivity Disorder, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Attention Deficit Hyperactivity Disorder Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Attention Deficit Hyperactivity Disorder Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: SPN-812
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: Guanfacine hydrochloride (TAK-503)
- 10.2.3 Drug: HLD200
- 10.2.4 Drug: AK0901 Capsule
- 10.2.5 Drug: NRCT-101SR
- 10.2.6 Other Drugs
- 11 Attention Deficit Hyperactivity Disorder Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Oral CBD Oil Enriched with Terpenes
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Tolcapone
- 11.2.3 Drug: Cannabigerol
- 11.2.4 Other Drugs
- 12 Attention Deficit Hyperactivity Disorder Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: Methylphenidate Pill
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Attention Deficit Hyperactivity Disorder Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Attention Deficit Hyperactivity Disorder, Key Drug Pipeline Companies
- 14.1 Otsuka Pharmaceutical Development & Commercialization, Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Corium, Inc.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Supernus Pharmaceuticals, Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Ironshore Pharmaceuticals and Development, Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Neurocentria, Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Bazelet Nehushtan Ltd.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Shanghai Ark Biopharmaceutical Co., Ltd.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Premier Research Group plc.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Prometrika, LLC
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Takeda Development Center Americas, Inc.
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook